Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK152 in Healthy Volunteers and Alzheimer's Disease Patients
NCT07301502Phase 1Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing AK152 regimen with Placebo (2 arms). Primary endpoint: Adverse Events at 8 weeks. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
AK152
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07301502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07301502.